专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06890918B2 Pharmaceutical compositions including ACE/NEP inhibitors and bioavailability enhancers 失效
标题翻译：包括ACE / NEP抑制剂和生物利用度增强剂的药物组合物
公开(公告)号：US06890918B2
公开(公告)日：2005-05-10
申请号：US10134651
申请日：2002-04-30
申请人： Beth Burnside , Rong-Kun Chang , Amir Shojaei
发明人： Beth Burnside , Rong-Kun Chang , Amir Shojaei
IPC分类号： A61K9/48 , A61K31/197 , A61K31/198 , A61K31/343 , A61K31/357 , A61K31/40 , A61K31/4365 , A61K31/554 , A61K38/00 , A61K45/00 , A61K45/08 , A61K47/12 , A61K47/18 , A61K47/20 , A61K47/22 , A61K47/28 , A61P9/00 , A61P9/04 , A61P9/12 , A61K31/195 , A61K31/36
CPC分类号： A61K47/28 , A61K9/485 , A61K9/4858 , A61K31/197 , A61K31/198 , A61K31/343 , A61K31/357 , A61K31/40 , A61K31/554 , A61K47/12 , A61K47/20 , A61K47/22
摘要： A pharmaceutical composition comprising an inhibitor of angiotensin converting enzyme and neutral endopeptidase, such as sampatrilat, and at least one bioavailability enhancer such as an organic acid, e.g., ascorbic acid. Such a composition has improved systemic bioavailability.
摘要翻译：一种药物组合物，其包含血管紧张素转换酶抑制剂和中性内肽酶，诸如血管舒张肽，以及至少一种生物利用度增强剂，例如有机酸，例如抗坏血酸。这种组合物具有改善的全身生物利用度。

2. 发明申请

US20050158384A1 Sustained release delivery of amphetamine salts 审中-公开
标题翻译：持续释放苯丙胺盐
公开(公告)号：US20050158384A1
公开(公告)日：2005-07-21
申请号：US11030174
申请日：2005-01-07
申请人： Richard Couch , Beth Burnside , Rong-Kun Chang
发明人： Richard Couch , Beth Burnside , Rong-Kun Chang
IPC分类号： A61K20060101 , A61K9/22 , A61K9/50 , A61K9/54 , A61K31/137 , A61K31/205
CPC分类号： A61K9/5015 , A61K9/5026 , A61K9/5047 , A61K31/137 , A61K31/205
摘要： A pharmaceutical composition comprises a once-a-day sustained release formulation of at least one amphetamine salt which provides mean plasma concentration profile aspects in human ADHD patients which are substantially the same as that provided by ADDERALL XR® type pulsatile formulations.
摘要翻译：药物组合物包含至少一种苯丙胺盐的一日一次持续释放制剂，其提供与ADDERALL XR型脉冲制剂基本上相同的人ADHD患者的平均血浆浓度分布方面。

3. 发明申请

US20050142187A1 Enhanced absorption of modified release dosage forms 审中-公开
标题翻译：增强了释放剂型的吸收
公开(公告)号：US20050142187A1
公开(公告)日：2005-06-30
申请号：US11021309
申请日：2004-12-23
申请人： Donald Treacy , Henry Flanner , Robert Guttendorf , Beth Burnside
发明人： Donald Treacy , Henry Flanner , Robert Guttendorf , Beth Burnside
IPC分类号： A61K9/16 , A61K9/50 , A61K31/43 , A61K9/20 , A61K9/48
CPC分类号： A61K9/1635 , A61K9/1641 , A61K9/1652 , A61K9/5073 , A61K31/43
摘要： Disclosed are products and methods for improving the plasma profile in a patient being treated with a pharmaceutical active agent that is subject to a limited window of absorption, which products and methods comprise orally administering the active agent in multiparticulate form, such that at least a portion thereof is delivered to the intestine while the patient is in the fed condition.
摘要翻译：公开了用于改善患有受限于有吸收吸收窗口的药物活性剂治疗的患者的血浆分布的产物和方法，该产品和方法包括以多颗粒形式口服施用活性剂，使得至少一部分当患者处于进食状态时，将其输送到肠道。

4. 发明申请

US20050019403A1 Antibiotic product, use and formulation thereof 有权
标题翻译：抗生素产品，其用途和配方
公开(公告)号：US20050019403A1
公开(公告)日：2005-01-27
申请号：US10894994
申请日：2004-07-20
申请人： Beth Burnside , Henry Flanner , Colin Rowlings
发明人： Beth Burnside , Henry Flanner , Colin Rowlings
IPC分类号： A61K9/20 , A61K9/22 , A61K9/48 , A61K9/52 , A61K9/54 , A61P31/00
CPC分类号： A61K9/5084 , A61K9/2077 , A61K9/4808
摘要： An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, a delayed release dosage form, and a sustained release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
摘要翻译：抗生素产品由至少三种剂型形成，每种剂型具有不同的释放特征，抗生素产物的C max在小于约十二小时内达到。在一个实施方案中，存在立即释放剂型，延迟释放剂型和持续释放剂型，其中每种剂型具有不同的释放特征，其中各自在不同时间达到C max。

5. 发明申请

US20050019402A1 Antibiotic product, use and formulation thereof 有权
标题翻译：抗生素产品，其用途和配方
公开(公告)号：US20050019402A1
公开(公告)日：2005-01-27
申请号：US10894787
申请日：2004-07-20
申请人： Beth Burnside , Henry Flanner , Colin Rowlings
发明人： Beth Burnside , Henry Flanner , Colin Rowlings
IPC分类号： A61K9/20 , A61K9/22 , A61K9/48 , A61P31/00
CPC分类号： A61K9/4808 , A61K9/2077
摘要： An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more sustained release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
摘要翻译：抗生素产品由至少三种剂型形成，每种剂型具有不同的释放特征，抗生素产物的C max在小于约十二小时内达到。在一个实施方案中，存在立即释放剂型，以及两种或更多种缓释剂型，其中每种剂型具有不同的释放特征，其中各自在不同时间达到Cmax。

6. 发明申请

US20060193908A1 Extended release formulations of poorly soluble antibiotics 审中-公开
标题翻译：难溶性抗生素的延长释放制剂
公开(公告)号：US20060193908A1
公开(公告)日：2006-08-31
申请号：US11267943
申请日：2005-11-04
申请人： Beth Burnside , Colin Rowlings , Sandra Wassink , Donald Treacy , John Koleng
发明人： Beth Burnside , Colin Rowlings , Sandra Wassink , Donald Treacy , John Koleng
IPC分类号： A61K31/7048 , A61K9/20
CPC分类号： A61K9/2077 , A61K9/2009 , A61K9/2018 , A61K31/7048
摘要： An extended release pharmaceutical compressed composition and dosage form comprising poorly water soluble macrolide antibiotic, surfactant and non-lipophilic, non-polymeric excipient is disclosed. The composition releases the macrolide antibiotic over an extended period of time, generally at least over 12 hours, even in the absence of a release rate-retarding polymer, release rate-retarding coating or release rate-retarding lipophilic excipient. The composition is suitable for once daily or twice daily oral administration for the treatment of many different types of bacterial infections. One embodiment of the compressed composition includes a drug-containing granular composition and a binding composition, wherein the two are mixed together and then compressed into a tablet or pill. The surfactant is in admixture with or coated onto the macrolide antibiotic, and it can be included in the granular composition and/or the binding composition. The non-polymeric, non-lipophilic excipient is included in the granular composition and/or the binding composition.
摘要翻译：公开了包含难溶于水的大环内酯类抗生素，表面活性剂和非亲脂性非聚合物赋形剂的延长释放药物压缩组合物和剂型。即使在没有释放速率阻滞性聚合物，释放速率阻滞涂层或释放速率延缓的亲脂性赋形剂的情况下，该组合物延长的时间段（通常至少超过12小时）释放大环内酯类抗生素。该组合物适合于每天一次或每天两次口服给药以治疗许多不同类型的细菌感染。压缩组合物的一个实施方案包括含药物的颗粒组合物和结合组合物，其中两者混合在一起，然后压制成片剂或药丸。表面活性剂与大环内酯类抗生素混合或涂覆在其上，并且可以包含在颗粒组合物和/或粘合组合物中。非聚合的非亲脂性赋形剂包括在颗粒组合物和/或粘合组合物中。

7. 发明申请

US20050058708A1 Antibiotic product, use and formulation thereof 有权
公开(公告)号：US20050058708A1
公开(公告)日：2005-03-17
申请号：US10940265
申请日：2004-09-14
申请人： Beth Burnside , Henry Flanner , Colin Rowlings
发明人： Beth Burnside , Henry Flanner , Colin Rowlings
IPC分类号： A61K9/20 , A61K9/22 , A61K9/50 , A61K45/06 , A61K9/00
CPC分类号： A61K9/5073 , A61K9/1635 , A61K9/1641 , A61K9/1652 , A61K9/2077 , A61K9/2081 , A61K9/5026 , A61K9/5042 , A61K9/5047 , A61K9/5084 , A61K45/06
摘要： An antibiotic product is comprised of at least three dosage forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours after the initial release of antibiotic. In one embodiment, there are two delayed release dosage forms, as well as a delayed sustained release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.

8. 发明申请

US20070134327A1 Compositions and methods for improved efficacy of penicillin-type antibiotics 有权
标题翻译：用于提高青霉素型抗生素功效的组合物和方法
公开(公告)号：US20070134327A1
公开(公告)日：2007-06-14
申请号：US11636291
申请日：2006-12-08
申请人： Henry Flanner , Robert Guttendorf , Susan Clausen , Donald Treacy , Beth Burnside
发明人： Henry Flanner , Robert Guttendorf , Susan Clausen , Donald Treacy , Beth Burnside
IPC分类号： A61K9/22 , A61K31/43
CPC分类号： A61K9/2081 , A61K9/1652 , A61K9/5026 , A61K31/43
摘要： Disclosed are once-a-day penicillin-type antibiotic products comprising at least one modified release dosage form comprising penicillin-type antibiotics and pharmaceutically acceptable carriers, which compositions provide T>MIC90 in the serum for at least 5 hours (preferably for at least five consecutive hours), within a 24-hour dosing interval, for a given bacterial pathogen's MIC90, while providing a total dosage of the penicillin-type antibiotic for a 24-hour dosing interval.
摘要翻译：公开了一种包含至少一种包含青霉素型抗生素和药学上可接受的载体的至少一种修饰释放剂型的青霉素型抗生素产品，该组合物至少提供血清中的T> MIC 90 对于给定的细菌病原体的MIC 90，在24小时给药间隔内5小时（优选至少连续5小时），同时为24-剂量的青霉素型抗生素提供总剂量，小时给药间隔。

9. 发明申请

US20050048114A1 Antibiotic product, use and formulation thereof 有权
标题翻译：抗生素产品，其用途和配方
公开(公告)号：US20050048114A1
公开(公告)日：2005-03-03
申请号：US10922412
申请日：2004-08-20
申请人： Beth Burnside , Henry Flanner , Colin Rowlings
发明人： Beth Burnside , Henry Flanner , Colin Rowlings
IPC分类号： A61K20060101 , A61K9/14 , A61K9/20 , A61K9/22 , A61K9/24 , A61K9/50 , A61K9/52 , A61K9/54 , A61K31/00 , A61P31/04
CPC分类号： A61K31/00 , A61K9/1635 , A61K9/1652 , A61K9/2027 , A61K9/2077 , A61K9/2081 , A61K9/2846 , A61K9/2866 , A61K9/5026 , A61K9/5042 , A61K9/5084 , A61K31/43 , A61K31/496 , A61K31/546 , A61K31/7048
摘要： An antibiotic product is comprised of at least three dosage forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours after the initial release of antibiotic. In one embodiment, there are two delayed release dosage forms, as well as a delayed sustained release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
摘要翻译：抗生素产品由至少三种剂型组成，每种剂型具有不同的释放特征，抗生素产物的C max在抗生素初次释放后少于约十二小时内达到。在一个实施方案中，存在两种延迟释放剂型，以及延迟缓释剂型，其中每种剂型具有不同的释放特征，其中各自在不同时间达到C max。

10. 发明申请

US20050019401A1 Antibiotic product, use and formulation thereof 有权
标题翻译：抗生素产品，其用途和配方
公开(公告)号：US20050019401A1
公开(公告)日：2005-01-27
申请号：US10894786
申请日：2004-07-20
申请人： Beth Burnside , Henry Flanner , Colin Rowlings
发明人： Beth Burnside , Henry Flanner , Colin Rowlings
IPC分类号： A61K9/20 , A61K9/22 , A61P31/00
CPC分类号： A61K31/54 , A61K9/2077 , A61K31/545 , A61K31/7048
摘要： An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, a sustained release dosage form, and a delayed release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
摘要翻译：抗生素产品由至少三种剂型形成，每种剂型具有不同的释放特征，抗生素产物的C max在小于约十二小时内达到。在一个实施方案中，存在立即释放剂型，持续释放剂型和延迟释放剂型，其中每种剂型具有不同的释放曲线，其中各自在不同时间达到Cmax。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式